Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2014

View Archived Issues

Baxter restructures agreement with Xenetic Biosciences and provides pipeline update

Researchers characterize antifungal activity EV-086

Glycopolymers used to uncover the mechanistic basis of tumor immunoprotection

Pazopanib demonstrates activity in patients with germ cell tumors

Sorafenib activity limited in patients with germ cell tumors

Chugai Pharmaceutical presents highlights of fourth quarter 2013

Phase II/III trial of Stallergenes' house dust mite immunotherapy tablets meets primary endpoint

AstraZeneca completes purchase of Bristol-Myers Squibb's global diabetes business

Burnet Institute receives grant to evaluate HIV test

Portola enters second collaboration with Bayer and Janssen for andexanet alfa

Chinese researchers present novel acetylcholinesterase inhibitors for Alzheimer's disease

New chimeric proteins patented by Biogen Idec and Amunix Operating

Omeros reports data from phase I trial of OMS-721

Phase Ib trial evaluates ONT-380 in breast cancer

Yong Guang Pharmaceutical discloses novel agents for cancer

U.S. group claims new HDAC4 inhibitors for Huntington's disease

Scientists in China synthesize new CETP inhibitors

Grastek obtains approval in Canada for grass pollen-induced allergic rhinitis

Tecfidera obtains approval in Europe for multiple sclerosis

Agios Pharmaceuticals opts for U.S. rights to IDH1 program

U.S. Navy approves phase I trial of Multikine in patients with HIV/HPV and perianal warts

FDA grants breakthrough therapy designation to eltrombopag

Tetrandrine demonstrates ability to protect against Ebola virus challenge in vivo

Ferrer collaborates with Ergomed and Ildong Pharmaceuticals for lorediplon

Kyowa Hakko Kirin initiates phase III study of ARQ-197 for HCC in Japan

Dainippon Sumitomo Pharma offers overview of third quarter of fiscal 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...